Drugs / IX001 TCR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06487377 | Jul 2024 → Mar 2025 overdue | colorectal cancer, malignant pancreatic neoplasm | Shanghai Pudong Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IX001 TCR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06487377 ↗ |
| Modality | Cell therapy | “IX001 TCR-T (T cell receptor-engineered T-Cell) injection” NCT06487377 ↗ |
| Route | Intravenous | “TCR-T cells will be administered via intravenous infusion” NCT06487377 ↗ |
| Target | KRAS | “IX001 TCR-T cells targeted for KRAS mutation” NCT06487377 ↗ |